Exact Mass: 680.413541

Exact Mass Matches: 680.413541

Found 423 metabolites which its exact mass value is equals to given mass value 680.413541, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

13-Sophorosyloxydocosanoic acid

13-[(2-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy]docosanoic acid

C34H64O13 (680.4346694000001)


   

Gingerglycolipid C

2-Hydroxy-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl (9Z)-octadec-9-enoic acid

C33H60O14 (680.398286)


Gingerglycolipid C is found in ginger. Gingerglycolipid C is from Zingiber officinale (ginger). From Zingiber officinale (ginger). Gingerglycolipid C is found in herbs and spices and ginger.

   

PA(15:0/20:5(5Z,8Z,11Z,14Z,17Z))

[(2R)-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyloxy]-3-(pentadecanoyloxy)propoxy]phosphonic acid

C38H65O8P (680.441682)


PA(15:0/20:5(5Z,8Z,11Z,14Z,17Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(15:0/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of eicosapentaenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(20:5(5Z,8Z,11Z,14Z,17Z)/15:0)

[(2R)-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyloxy]-2-(pentadecanoyloxy)propoxy]phosphonic acid

C38H65O8P (680.441682)


PA(20:5(5Z,8Z,11Z,14Z,17Z)/15:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:5(5Z,8Z,11Z,14Z,17Z)/15:0), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PG(a-13:0/i-16:0)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-(10-methyldodecanoyloxy)propan-2-yl] 14-methylpentadecanoate

C35H69O10P (680.4628104)


PG(a-13:0/i-16:0) is a phosphatidylglycerol - a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(a-13:0/i-16:0), in particular, consists of one chain of anteisotridecanoic acid at the C-1 position and one chain of isohexadecanoic acid at the C-2 position. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for cardiolipin synthesis.

   

PG(i-12:0/a-17:0)

[(2S)-2,3-dihydroxypropoxy][(2R)-2-[(14-methylhexadecanoyl)oxy]-3-[(10-methylundecanoyl)oxy]propoxy]phosphinic acid

C35H69O10P (680.4628104)


PG(i-12:0/a-17:0) is a phosphatidylglycerol - a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(i-12:0/a-17:0), in particular, consists of one chain of isododecanoic acid at the C-1 position and one chain of anteisoheptadecanoic acid at the C-2 position. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for cardiolipin synthesis.

   

PG(i-12:0/i-17:0)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-(10-methylundecanoyloxy)propan-2-yl] 15-methylhexadecanoate

C35H69O10P (680.4628104)


PG(i-12:0/i-17:0) is a phosphatidylglycerol - a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(i-12:0/i-17:0), in particular, consists of one chain of isododecanoic acid at the C-1 position and one chain of isoheptadecanoic acid at the C-2 position. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for cardiolipin synthesis.

   

PG(i-13:0/i-16:0)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-(11-methyldodecanoyloxy)propan-2-yl] 14-methylpentadecanoate

C35H69O10P (680.4628104)


PG(i-13:0/i-16:0) is a phosphatidylglycerol - a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(i-13:0/i-16:0), in particular, consists of one chain of isotridecanoic acid at the C-1 position and one chain of isohexadecanoic acid at the C-2 position. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for cardiolipin synthesis.

   

PG(i-14:0/a-15:0)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-(12-methyltridecanoyloxy)propan-2-yl] 12-methyltetradecanoate

C35H69O10P (680.4628104)


PG(i-14:0/a-15:0) is a phosphatidylglycerol - a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(i-14:0/a-15:0), in particular, consists of one chain of isotetradecanoic acid at the C-1 position and one chain of anteisopentadecanoic acid at the C-2 position. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for cardiolipin synthesis.

   

PG(i-14:0/i-15:0)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-(12-methyltridecanoyloxy)propan-2-yl] 13-methyltetradecanoate

C35H69O10P (680.4628104)


PG(i-14:0/i-15:0) is a phosphatidylglycerol - a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(i-14:0/i-15:0), in particular, consists of one chain of isotetradecanoic acid at the C-1 position and one chain of isopentadecanoic acid at the C-2 position. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for cardiolipin synthesis.

   

Tenuifolin

2-hydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicene-4,8a-dicarboxylic acid

C36H56O12 (680.3771576)


   

PA(12:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

[(2R)-3-(dodecanoyloxy)-2-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(12:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 4-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/12:0), in particular, consists of one chain of one 4-hydroxy-docosahexaenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

[(2R)-3-(dodecanoyloxy)-2-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(12:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 7-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/12:0), in particular, consists of one chain of one 7-hydroxy-docosahexaenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

[(2R)-3-(dodecanoyloxy)-2-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(12:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 14-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/12:0), in particular, consists of one chain of one 14-hydroxy-docosahexaenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

[(2R)-3-(dodecanoyloxy)-2-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(12:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 17-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/12:0), in particular, consists of one chain of one 17-hydroxy-docosahexaenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

[(2R)-3-(dodecanoyloxy)-2-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(12:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 16,17-epoxy-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/12:0), in particular, consists of one chain of one 16,17-epoxy-docosapentaenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5))

[(2R)-2-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(14:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/14:1(9Z))

[(2R)-3-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(20:4(6E,8Z,11Z,14Z)+=O(5)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)+=O(5)/14:1(9Z)), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:4(5Z,8Z,11Z,13E)+=O(15))

[(2R)-2-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(14:1(9Z)/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/14:1(9Z))

[(2R)-3-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(20:4(5Z,8Z,11Z,13E)+=O(15)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)+=O(15)/14:1(9Z)), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

[(2R)-2-{[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:1(9Z))

[(2R)-3-{[(5Z,8Z,11Z,14Z,16E,18S)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:1(9Z)), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

[(2R)-2-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:1(9Z))

[(2R)-3-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:1(9Z)), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

[(2R)-2-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(14:1(9Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:1(9Z))

[(2R)-3-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:1(9Z)), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

[(2R)-2-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(14:1(9Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:1(9Z))

[(2R)-3-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:1(9Z)), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

[(2R)-2-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(i-12:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 4-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/i-12:0)

[(2R)-3-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/i-12:0), in particular, consists of one chain of one 4-hydroxy-docosahexaenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

[(2R)-2-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(i-12:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 7-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/i-12:0)

[(2R)-3-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/i-12:0), in particular, consists of one chain of one 7-hydroxy-docosahexaenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

[(2R)-2-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(i-12:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 14-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/i-12:0)

[(2R)-3-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/i-12:0), in particular, consists of one chain of one 14-hydroxy-docosahexaenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

[(2R)-2-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(i-12:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 17-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/i-12:0)

[(2R)-3-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/i-12:0), in particular, consists of one chain of one 17-hydroxy-docosahexaenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

[(2R)-3-[(10-methylundecanoyl)oxy]-2-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(i-12:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 16,17-epoxy-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/i-12:0)

[(2R)-2-[(10-methylundecanoyl)oxy]-3-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}propoxy]phosphonic acid

C37H61O9P (680.4052985999999)


PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/i-12:0), in particular, consists of one chain of one 16,17-epoxy-docosapentaenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Tenuifolin

(2S,3R,4S,4aR,6aR,6bR,8aS,12aS,14aR,14bR)-2-hydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid

C36H56O12 (680.3771576)


Tenuifolin is a natural product found in Polygala comosa, Muraltia spinosa, and other organisms with data available. Tenuifolin is a triterpene isolated from Polygala tenuifolia?Willd, has neuroprotective effects. Tenuifolin reduces Aβ secretion by inhibiting β-secretase. Tenuifolin improves learning and memory in aged mice by decreasing AChE activity and has the potential for Alzheimer’s disease (AD) treatment[1]. Tenuifolin is a triterpene isolated from Polygala tenuifolia?Willd, has neuroprotective effects. Tenuifolin reduces Aβ secretion by inhibiting β-secretase. Tenuifolin improves learning and memory in aged mice by decreasing AChE activity and has the potential for Alzheimer’s disease (AD) treatment[1].

   
   
   
   

2-(beta-D-glucopyranosyloxy)-3,16,20-trihydroxy-9-methyl-19-norlanosta-5,24-diene-22-one

2-(beta-D-glucopyranosyloxy)-3,16,20-trihydroxy-9-methyl-19-norlanosta-5,24-diene-22-one

C36H56O12 (680.3771576)


   
   
   
   

(2R,3R,4R,6aR,6bS,8aR,14bR)-2,3,12-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

(2R,3R,4R,6aR,6bS,8aR,14bR)-2,3,12-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


   

16alpha,23alpha-epoxy-2beta,3beta,7beta,20beta,26-pentahydroxy-10alpha,23alpha-cucurbit-5,24-(E)-dien-11-one 2-O-beta-D-glucopyranoside

16alpha,23alpha-epoxy-2beta,3beta,7beta,20beta,26-pentahydroxy-10alpha,23alpha-cucurbit-5,24-(E)-dien-11-one 2-O-beta-D-glucopyranoside

C36H56O12 (680.3771576)


   
   
   
   

2alpha,3beta,19alpha,23-tetrahydroxy-11-oxo-olean-12-en-28-oic acid 28-O-beta-D-glucopyranosyl ester

2alpha,3beta,19alpha,23-tetrahydroxy-11-oxo-olean-12-en-28-oic acid 28-O-beta-D-glucopyranosyl ester

C36H56O12 (680.3771576)


   

alpha-D-glucopyranosyl ester of 2alpha,3beta,19alpha,23-tetrahydroxy-12-ursen-28-oic acid

alpha-D-glucopyranosyl ester of 2alpha,3beta,19alpha,23-tetrahydroxy-12-ursen-28-oic acid

C37H60O11 (680.413541)


   

(2R,3R,2R,3R)-nostoxanthin 3-sulfate|nostoxanthin monosulfate

(2R,3R,2R,3R)-nostoxanthin 3-sulfate|nostoxanthin monosulfate

C40H56O7S (680.3746546)


   

6-acetylginsenoside F1|6-O-Acetyl ginsenoside F1

6-acetylginsenoside F1|6-O-Acetyl ginsenoside F1

C38H64O10 (680.4499244)


   
   

olean-3alpha,5alpha,25-triol-12-en-23,28-dioic acid 3-beta-D-glucopyranoside|termiarjunoside II

olean-3alpha,5alpha,25-triol-12-en-23,28-dioic acid 3-beta-D-glucopyranoside|termiarjunoside II

C36H56O12 (680.3771576)


   

Fusicoccin from Fusicoccum amygdali

Fusicoccin from Fusicoccum amygdali

C36H56O12 (680.3771576)


   

(3S,3R)-Astaxanthindiacetat|(3S,3S)-Astaxanthin-diacetat|all-trans-(3S,3S) astaxanthin diacetate|Astaxanthin-diacetat|Astaxanthin-ester|Astaxanthindiacetat

(3S,3R)-Astaxanthindiacetat|(3S,3S)-Astaxanthin-diacetat|all-trans-(3S,3S) astaxanthin diacetate|Astaxanthin-diacetat|Astaxanthin-ester|Astaxanthindiacetat

C44H56O6 (680.4076676)


   
   

2-beta-Glucopyranosyl-dihydrocucurbitacin D|2-O-beta-D-glucopyranosyl-23,24-dihydrocucurbitacin D|arvenin IV|cucurbitacin R-glucoside

2-beta-Glucopyranosyl-dihydrocucurbitacin D|2-O-beta-D-glucopyranosyl-23,24-dihydrocucurbitacin D|arvenin IV|cucurbitacin R-glucoside

C36H56O12 (680.3771576)


   
   

20(S),24(R)-epoxydammaran-3beta,11alpha,25-triol 3-O-beta-D-2-O-acetylglucopyranoside

20(S),24(R)-epoxydammaran-3beta,11alpha,25-triol 3-O-beta-D-2-O-acetylglucopyranoside

C38H64O10 (680.4499244)


   

2-[(E)-2-{3-[(2E)-3,7-dimethyl-2,6-octadienyl]-5-carboxy-2-hydroxyphenyl}ethenyl]-8-[(2E)-3,7-dimethyl-2,6-octadienyl]-2-methyl-4-(2-methyl-1-propenyl)-6-chromancarboxylic acid

2-[(E)-2-{3-[(2E)-3,7-dimethyl-2,6-octadienyl]-5-carboxy-2-hydroxyphenyl}ethenyl]-8-[(2E)-3,7-dimethyl-2,6-octadienyl]-2-methyl-4-(2-methyl-1-propenyl)-6-chromancarboxylic acid

C44H56O6 (680.4076676)


   

(20SR,24RS)-16beta-acetoxy-20,24-epoxy-9,19-cyclolanostane-3beta,15alpha,18,25-tetraol-3-O-beta-D-xylopyranoside

(20SR,24RS)-16beta-acetoxy-20,24-epoxy-9,19-cyclolanostane-3beta,15alpha,18,25-tetraol-3-O-beta-D-xylopyranoside

C37H60O11 (680.413541)


   

3beta-O-beta-D-xylopyranosyl-24-O-acetoxy-1alpha,25-dihydroxylcycloartan-28-oic acid|nerviside C

3beta-O-beta-D-xylopyranosyl-24-O-acetoxy-1alpha,25-dihydroxylcycloartan-28-oic acid|nerviside C

C37H60O11 (680.413541)


   

6?-O-acetylginsenoside Rh1

6?-O-acetylginsenoside Rh1

C38H64O10 (680.4499244)


   

19alpha-hydroxy-2,3-secours-12-en-2,3,28-trioic acid 28-O-beta-D-glucopyranosyl ester|potentillanoside D

19alpha-hydroxy-2,3-secours-12-en-2,3,28-trioic acid 28-O-beta-D-glucopyranosyl ester|potentillanoside D

C36H56O12 (680.3771576)


   

3-Ketone,2-O-beta-D-Glucopyranoside-(2beta,3beta,16alpha,20(,24(,25()-20,24-Epoxy-2,3,16,25,26-pentahydroxycucurbit-5-en-11-one|3-Ketone,2-O-beta-D-Glucopyranoside-(2beta,3beta,16alpha,20xi,24xi,25xi)-20,24-Epoxy-2,3,16,25,26-pentahydroxycucurbit-5-en-11-one

3-Ketone,2-O-beta-D-Glucopyranoside-(2beta,3beta,16alpha,20(,24(,25()-20,24-Epoxy-2,3,16,25,26-pentahydroxycucurbit-5-en-11-one|3-Ketone,2-O-beta-D-Glucopyranoside-(2beta,3beta,16alpha,20xi,24xi,25xi)-20,24-Epoxy-2,3,16,25,26-pentahydroxycucurbit-5-en-11-one

C36H56O12 (680.3771576)


   
   

16-oxolyclanitin-29-yl E-4-hydroxyl-3-methoxycinnamate

16-oxolyclanitin-29-yl E-4-hydroxyl-3-methoxycinnamate

C40H56O9 (680.3924126000001)


   

methyl 3-O-beta-D-glucopyranosylpolygalacate|Methyl-3-O-??-D-glucopyranosyl polygalacate

methyl 3-O-beta-D-glucopyranosylpolygalacate|Methyl-3-O-??-D-glucopyranosyl polygalacate

C37H60O11 (680.413541)


   
   

Methyl-2alpha,3beta-dibenzoyloxy-urs-12-en-28-oat

Methyl-2alpha,3beta-dibenzoyloxy-urs-12-en-28-oat

C44H56O6 (680.4076676)


   
   
   
   
   
   
   
   
   
   

Suavissimoside F1

(2R,3R,4S,4aR,6aR,6bS,8aS,11R,12R,12aS,14aR,14bR)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


Suavissimoside R1 is a natural product found in Rubus chingii var. suavissimus, Trachelospermum asiaticum, and other organisms with data available.

   

C36H56O12_beta-D-Glucopyranose, 1-O-[(2alpha,3beta,5xi,9xi)-2,3,19,24-tetrahydroxy-24,28-dioxours-12-en-28-yl]

NCGC00169718-03_C36H56O12_beta-D-Glucopyranose, 1-O-[(2alpha,3beta,5xi,9xi)-2,3,19,24-tetrahydroxy-24,28-dioxours-12-en-28-yl]-

C36H56O12 (680.3771576)


   

C36H56O12_beta-D-Glucopyranose, 1-O-[(2alpha,3beta,5xi,9xi,18xi)-2,3,19,24-tetrahydroxy-24,28-dioxoolean-12-en-28-yl]

NCGC00385360-01_C36H56O12_beta-D-Glucopyranose, 1-O-[(2alpha,3beta,5xi,9xi,18xi)-2,3,19,24-tetrahydroxy-24,28-dioxoolean-12-en-28-yl]-

C36H56O12 (680.3771576)


   

(2R,3R,4R,6aR,6bS,8aS,11R,12R,12aS,14bR)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

(2R,3R,4R,6aR,6bS,8aS,11R,12R,12aS,14bR)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


   

2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


   

(2R,3R,4R,6aR,6bS,8aR,14bR)-2,3,12-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid_major

(2R,3R,4R,6aR,6bS,8aR,14bR)-2,3,12-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid_major

C36H56O12 (680.3771576)


   

(2R,3R,4R,6aR,6bS,8aS,11R,12R,12aS,14bR)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid_minor

(2R,3R,4R,6aR,6bS,8aS,11R,12R,12aS,14bR)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid_minor

C36H56O12 (680.3771576)


   

(2R,3R,4R,6aR,6bS,8aR,14bR)-2,3,12-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid_minor

(2R,3R,4R,6aR,6bS,8aR,14bR)-2,3,12-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid_minor

C36H56O12 (680.3771576)


   

(2R,3R,4R,6aR,6bS,8aS,11R,12R,12aS,14bR)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid_major

(2R,3R,4R,6aR,6bS,8aS,11R,12R,12aS,14bR)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid_major

C36H56O12 (680.3771576)


   

(2R,3R,4R,6aR,6bS,8aS,11R,12R,12aS,14bR)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid_72.4\\%

(2R,3R,4R,6aR,6bS,8aS,11R,12R,12aS,14bR)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid_72.4\\%

C36H56O12 (680.3771576)


   

KFKMK

Lys-Phe-Lys-Met-Lys

C32H56N8O6S (680.4043316)


   

1,2-ditetradecanoyl-sn-glycero-3-phosphosulfocholine

1,2-ditetradecanoyl-sn-glycero-3-phosphosulfocholine

C35H69O8PS (680.4450524)


   

PG(12:0/17:0)

1-dodecanoyl-2-heptadecanoyl-glycero-3-phospho-(1-sn-glycerol)

C35H69O10P (680.4628104)


   

PG(13:0/16:0)

1-tridecanoyl-2-hexadecanoyl-glycero-3-phospho-(1-sn-glycerol)

C35H69O10P (680.4628104)


   

PG(15:0/14:0)

1-pentadecanoyl-2-tetradecanoyl-glycero-3-phospho-(1-sn-glycerol)

C35H69O10P (680.4628104)


   

PG(16:0/13:0)

1-hexadecanoyl-2-tridecanoyl-glycero-3-phospho-(1-sn-glycerol)

C35H69O10P (680.4628104)


   

PG(17:0/12:0)

1-heptadecanoyl-2-dodecanoyl-glycero-3-phospho-(1-sn-glycerol)

C35H69O10P (680.4628104)


   

PG(14:0/15:0)

1-tetradecanoyl-2-pentadecanoyl-glycero-3-phospho-(1-sn-glycerol)

C35H69O10P (680.4628104)


   

PA(15:0/20:5(5Z,8Z,11Z,14Z,17Z))

1-pentadecanoyl-2-(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)-glycero-3-phosphate

C38H65O8P (680.441682)


   

PA(15:1(9Z)/20:4(5Z,8Z,11Z,14Z))

1-(9Z-pentadecenoyl)-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-glycero-3-phosphate

C38H65O8P (680.441682)


   

PA(17:1(9Z)/18:4(6Z,9Z,12Z,15Z))

1-(9Z-heptadecenoyl)-2-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-glycero-3-phosphate

C38H65O8P (680.441682)


   

PA(17:2(9Z,12Z)/18:3(6Z,9Z,12Z))

1-(9Z,12Z-heptadecadienoyl)-2-(6Z,9Z,12Z-octadecatrienoyl)-glycero-3-phosphate

C38H65O8P (680.441682)


   

PA(17:2(9Z,12Z)/18:3(9Z,12Z,15Z))

1-(9Z,12Z-heptadecadienoyl)-2-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phosphate

C38H65O8P (680.441682)


   

PA(18:3(6Z,9Z,12Z)/17:2(9Z,12Z))

1-(6Z,9Z,12Z-octadecatrienoyl)-2-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphate

C38H65O8P (680.441682)


   

PA(18:3(9Z,12Z,15Z)/17:2(9Z,12Z))

1-(9Z,12Z,15Z-octadecatrienoyl)-2-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphate

C38H65O8P (680.441682)


   

PA(18:4(6Z,9Z,12Z,15Z)/17:1(9Z))

1-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-2-(9Z-heptadecenoyl)-glycero-3-phosphate

C38H65O8P (680.441682)


   

PA(20:4(5Z,8Z,11Z,14Z)/15:1(9Z))

1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-2-(9Z-pentadecenoyl)-glycero-3-phosphate

C38H65O8P (680.441682)


   

PA(20:5(5Z,8Z,11Z,14Z,17Z)/15:0)

1-(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)-2-pentadecanoyl-glycero-3-phosphate

C38H65O8P (680.441682)


   

Gingerglycolipid C

2-hydroxy-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl (9Z)-octadec-9-enoate

C33H60O14 (680.398286)


   

2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-(((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)carbonyl)-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicene-4-carboxylic acid

2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-(((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)carbonyl)-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


   

DGMG 18:1

1-(9Z-octadecenoy)l-3-O-(6-O-alpha-D-galactosyl-beta-D-galactosyl)-sn-glycerol

C33H60O14 (680.398286)


   

PG 29:0

1-tetradecanoyl-2-pentadecanoyl-glycero-3-phospho-(1-sn-glycerol)

C35H69O10P (680.4628104)


   

PA 35:5

1-(9Z,12Z,15Z-octadecatrienoyl)-2-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphate

C38H65O8P (680.441682)


   

OA-PG

1-(9Z-octadecenoyl)-2-azeloyl-sn-glycero-3-phospho-(1-sn-glycerol)

C33H61O12P (680.3900435999999)


   

Arvenin IV

Cucurbitacin R 2-O-beta-D-glucoside

C36H56O12 (680.3771576)


   

Glucopyranosyl-1-O-(4,4-diapo-7,8,11,12-tetrahydrolycopen-4-oate)-6-O-(2-methylbutanoate)

4-[(6-O-11-tetranoyl-b-D-glucopyranosyl)oxy]-7,8-dihydro-4,4-diapo-psi,psi-carotene-4-oic acid

C41H60O8 (680.428796)


   

Officinoterpenoside C

2alpha,3beta,24,29-tetrahydroxyolean-12-en-28-oic acid 28-O-beta-d-glucopyranside

C37H60O11 (680.413541)


   

Nostoxanthin sulfate

Nostoxanthin sulfate

C40H56O7S (680.3746546)


   
   

4-tert-butyl-calix[4]arene-crown-6-complex

4-tert-butyl-calix[4]arene-crown-6-complex

C44H56O6 (680.4076676)


   
   

methyl ((S)-1-((S)-2-(5-(4-(2-((S)-1-((S)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-4-yl)-[1,1-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate

methyl ((S)-1-((S)-2-(5-(4-(2-((S)-1-((S)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-4-yl)-[1,1-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate

C38H48N8O4 (680.3798327999999)


   

Penbutolol sulfate

Penbutolol sulfate

C36H60N2O8S (680.4070160000001)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents

   

2,3,12-Trihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

2,3,12-Trihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


   

Nostoxanthin 3-sulfate

Nostoxanthin 3-sulfate

C40H56O7S (680.3746546)


   
   

PA(12:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

PA(12:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C37H61O9P (680.4052985999999)


   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/12:0)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/12:0)

C37H61O9P (680.4052985999999)


   

PA(12:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

PA(12:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C37H61O9P (680.4052985999999)


   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/12:0)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/12:0)

C37H61O9P (680.4052985999999)


   

PA(14:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5))

PA(14:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5))

C37H61O9P (680.4052985999999)


   

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/14:1(9Z))

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/14:1(9Z))

C37H61O9P (680.4052985999999)


   

PA(14:1(9Z)/20:4(5Z,8Z,11Z,13E)+=O(15))

PA(14:1(9Z)/20:4(5Z,8Z,11Z,13E)+=O(15))

C37H61O9P (680.4052985999999)


   

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/14:1(9Z))

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/14:1(9Z))

C37H61O9P (680.4052985999999)


   

PA(14:1(9Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

PA(14:1(9Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C37H61O9P (680.4052985999999)


   

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:1(9Z))

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:1(9Z))

C37H61O9P (680.4052985999999)


   

PA(12:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

PA(12:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C37H61O9P (680.4052985999999)


   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/12:0)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/12:0)

C37H61O9P (680.4052985999999)


   

PA(12:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

PA(12:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C37H61O9P (680.4052985999999)


   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/12:0)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/12:0)

C37H61O9P (680.4052985999999)


   

PA(12:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

PA(12:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C37H61O9P (680.4052985999999)


   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/12:0)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/12:0)

C37H61O9P (680.4052985999999)


   

PA(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

PA(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C37H61O9P (680.4052985999999)


   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:1(9Z))

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:1(9Z))

C37H61O9P (680.4052985999999)


   

PA(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

PA(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C37H61O9P (680.4052985999999)


   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:1(9Z))

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:1(9Z))

C37H61O9P (680.4052985999999)


   

PA(14:1(9Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

PA(14:1(9Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C37H61O9P (680.4052985999999)


   

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:1(9Z))

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:1(9Z))

C37H61O9P (680.4052985999999)


   

PA(i-12:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

PA(i-12:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C37H61O9P (680.4052985999999)


   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/i-12:0)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/i-12:0)

C37H61O9P (680.4052985999999)


   

PA(i-12:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

PA(i-12:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C37H61O9P (680.4052985999999)


   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/i-12:0)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/i-12:0)

C37H61O9P (680.4052985999999)


   

PA(i-12:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

PA(i-12:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C37H61O9P (680.4052985999999)


   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/i-12:0)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/i-12:0)

C37H61O9P (680.4052985999999)


   

PA(i-12:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

PA(i-12:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C37H61O9P (680.4052985999999)


   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/i-12:0)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/i-12:0)

C37H61O9P (680.4052985999999)


   

PA(i-12:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

PA(i-12:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C37H61O9P (680.4052985999999)


   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/i-12:0)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/i-12:0)

C37H61O9P (680.4052985999999)


   
   

N-[(3S,9S,10S)-9-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]cyclohexanecarboxamide

N-[(3S,9S,10S)-9-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]cyclohexanecarboxamide

C37H52N4O8 (680.3784952000001)


   

N-[(3S,9S,10R)-9-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]cyclohexanecarboxamide

N-[(3S,9S,10R)-9-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]cyclohexanecarboxamide

C37H52N4O8 (680.3784952000001)


   

N-[(3R,9S,10R)-9-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]cyclohexanecarboxamide

N-[(3R,9S,10R)-9-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]cyclohexanecarboxamide

C37H52N4O8 (680.3784952000001)


   

N-[(3S,9S,10S)-9-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]cyclohexanecarboxamide

N-[(3S,9S,10S)-9-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]cyclohexanecarboxamide

C37H52N4O8 (680.3784952000001)


   

beta-Decaethylcalix[5]furan

beta-Decaethylcalix[5]furan

C45H60O5 (680.444051)


   

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (13Z,16Z)-tetracosa-13,16-dienoate

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (13Z,16Z)-tetracosa-13,16-dienoate

C33H61O12P (680.3900435999999)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate

C38H64O10 (680.4499244)


   

[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C38H64O10 (680.4499244)


   

[1-nonanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

[1-nonanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C38H64O10 (680.4499244)


   

[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C38H64O10 (680.4499244)


   

[1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C38H64O10 (680.4499244)


   

[1-[(Z)-tridec-9-enoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-[(Z)-tridec-9-enoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C38H64O10 (680.4499244)


   

[1-tridecanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-tridecanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C38H64O10 (680.4499244)


   

[1-[(2-Butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] pentacosanoate

[1-[(2-Butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] pentacosanoate

C35H69O10P (680.4628104)


   

[1-[(2-Heptanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] docosanoate

[1-[(2-Heptanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] docosanoate

C35H69O10P (680.4628104)


   

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] henicosanoate

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] henicosanoate

C35H69O10P (680.4628104)


   

[1-[(2-Hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] tricosanoate

[1-[(2-Hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] tricosanoate

C35H69O10P (680.4628104)


   

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] icosanoate

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] icosanoate

C35H69O10P (680.4628104)


   

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] tetracosanoate

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] tetracosanoate

C35H69O10P (680.4628104)


   

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] hexacosanoate

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] hexacosanoate

C35H69O10P (680.4628104)


   

[1-[(2-Acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] heptacosanoate

[1-[(2-Acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] heptacosanoate

C35H69O10P (680.4628104)


   

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-tridecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] hexadecanoate

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-tridecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] hexadecanoate

C35H69O10P (680.4628104)


   

[1-[(2-Decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] nonadecanoate

[1-[(2-Decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] nonadecanoate

C35H69O10P (680.4628104)


   

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-tetradecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] pentadecanoate

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-tetradecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] pentadecanoate

C35H69O10P (680.4628104)


   

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-undecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] octadecanoate

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-undecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] octadecanoate

C35H69O10P (680.4628104)


   

[1-[(2-Dodecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] heptadecanoate

[1-[(2-Dodecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] heptadecanoate

C35H69O10P (680.4628104)


   

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] henicosanoate

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] henicosanoate

C35H69O10P (680.4628104)


   

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] hexacosanoate

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] hexacosanoate

C35H69O10P (680.4628104)


   

[1-Acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] heptacosanoate

[1-Acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] heptacosanoate

C35H69O10P (680.4628104)


   

[1-Butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] pentacosanoate

[1-Butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] pentacosanoate

C35H69O10P (680.4628104)


   

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] icosanoate

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] icosanoate

C35H69O10P (680.4628104)


   

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] tricosanoate

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] tricosanoate

C35H69O10P (680.4628104)


   

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] tetracosanoate

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] tetracosanoate

C35H69O10P (680.4628104)


   

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] docosanoate

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] docosanoate

C35H69O10P (680.4628104)


   

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] heptadecanoate

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] heptadecanoate

C35H69O10P (680.4628104)


   

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] hexadecanoate

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] hexadecanoate

C35H69O10P (680.4628104)


   

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] pentadecanoate

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] pentadecanoate

C35H69O10P (680.4628104)


   

[1-Decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] nonadecanoate

[1-Decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] nonadecanoate

C35H69O10P (680.4628104)


   

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] octadecanoate

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] octadecanoate

C35H69O10P (680.4628104)


   

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C38H65O8P (680.441682)


   

(1-heptadecanoyloxy-3-phosphonooxypropan-2-yl) (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

(1-heptadecanoyloxy-3-phosphonooxypropan-2-yl) (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C38H65O8P (680.441682)


   

[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropyl] (9Z,12Z)-nonadeca-9,12-dienoate

[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropyl] (9Z,12Z)-nonadeca-9,12-dienoate

C38H65O8P (680.441682)


   

[1-[(Z)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[1-[(Z)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C38H65O8P (680.441682)


   

[1-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[1-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C38H65O8P (680.441682)


   

[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C38H65O8P (680.441682)


   

[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropyl] (Z)-nonadec-9-enoate

[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropyl] (Z)-nonadec-9-enoate

C38H65O8P (680.441682)


   

(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C38H65O8P (680.441682)


   

[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C38H65O8P (680.441682)


   

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] octadecanoate

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] octadecanoate

C35H69O10P (680.4628104)


   

[(2S,3S,6S)-6-[(2S)-2-decanoyloxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[(2S)-2-decanoyloxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C33H60O12S (680.380528)


   

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C38H65O8P (680.441682)


   

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C38H65O8P (680.441682)


   

[(2R)-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-undecanoyloxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[(2R)-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-undecanoyloxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C38H64O10 (680.4499244)


   

[(2R)-1-pentadecanoyloxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

[(2R)-1-pentadecanoyloxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C38H65O8P (680.441682)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C36H57O10P (680.3689152)


   

[(2R)-2-pentadecanoyloxy-3-phosphonooxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

[(2R)-2-pentadecanoyloxy-3-phosphonooxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C38H65O8P (680.441682)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] octadecanoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] octadecanoate

C35H69O10P (680.4628104)


   

2-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(E)-tridec-8-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(E)-tridec-8-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C37H63NO8P+ (680.4291068)


   

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C38H65O8P (680.441682)


   

[(2S)-1-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2S)-1-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C38H64O10 (680.4499244)


   

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] nonadecanoate

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] nonadecanoate

C35H69O10P (680.4628104)


   

[(2R)-1-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[(2R)-1-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C38H65O8P (680.441682)


   

[1-[(E)-tridec-8-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[1-[(E)-tridec-8-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C38H64O10 (680.4499244)


   

[(2R)-1-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2R)-1-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C38H65O8P (680.441682)


   

[(2R)-1-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

[(2R)-1-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C38H65O8P (680.441682)


   

[(2S,3S,6S)-6-[(2S)-3-decanoyloxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[(2S)-3-decanoyloxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C33H60O12S (680.380528)


   

[(2R)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] nonadecanoate

[(2R)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] nonadecanoate

C35H69O10P (680.4628104)


   

[(2R)-2-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2R)-2-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C38H65O8P (680.441682)


   

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C38H65O8P (680.441682)


   

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C38H65O8P (680.441682)


   

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-dodecanoyloxypropyl] heptadecanoate

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-dodecanoyloxypropyl] heptadecanoate

C35H69O10P (680.4628104)


   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] nonadecanoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] nonadecanoate

C38H65O8P (680.441682)


   

[(2S)-1-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[(2S)-1-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C38H64O10 (680.4499244)


   

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C38H65O8P (680.441682)


   

[(2R)-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-undecanoyloxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2R)-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-undecanoyloxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C38H64O10 (680.4499244)


   

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (10E,13E,16E)-nonadeca-10,13,16-trienoate

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (10E,13E,16E)-nonadeca-10,13,16-trienoate

C38H65O8P (680.441682)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C36H57O10P (680.3689152)


   

[(2R)-2-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[(2R)-2-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C38H65O8P (680.441682)


   

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (E)-nonadec-9-enoate

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (E)-nonadec-9-enoate

C38H65O8P (680.441682)


   

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (7E,9E)-nonadeca-7,9-dienoate

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (7E,9E)-nonadeca-7,9-dienoate

C38H65O8P (680.441682)


   

[(2R)-1-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

[(2R)-1-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C38H65O8P (680.441682)


   

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C38H65O8P (680.441682)


   

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C38H65O8P (680.441682)


   

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C38H65O8P (680.441682)


   

[1-tridecanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-tridecanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C38H64O10 (680.4499244)


   

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C38H65O8P (680.441682)


   

2-[[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-heptanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-heptanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C37H63NO8P+ (680.4291068)


   
   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-(12-methyltridecanoyloxy)propan-2-yl] 12-methyltetradecanoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-(12-methyltridecanoyloxy)propan-2-yl] 12-methyltetradecanoate

C35H69O10P (680.4628104)


   

1-hexadecanoyl-2-tridecanoyl-glycero-3-phospho-(1-sn-glycerol)

1-hexadecanoyl-2-tridecanoyl-glycero-3-phospho-(1-sn-glycerol)

C35H69O10P (680.4628104)


   

MGDG(29:4)

MGDG(18:2_11:2)

C38H64O10 (680.4499244)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

PAR-4 Agonist Peptide, amide

PAR-4 Agonist Peptide, amide

C34H48N8O7 (680.3645778)


PAR-4 Agonist Peptide, amide (PAR-4-AP; AY-NH2) is a proteinase-activated receptor-4 (PAR-4) agonist, which has no effect on either PAR-1 or PAR-2 and whose effects are blocked by a PAR-4 antagonist.

   

(3s,6r)-6-benzyl-8,10-dihydroxy-3-isopropyl-4,9-dimethyl-12-[(7r)-7-{[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octan-2-yl]-1-oxa-4,7-diazacyclododec-7-ene-2,5-dione

(3s,6r)-6-benzyl-8,10-dihydroxy-3-isopropyl-4,9-dimethyl-12-[(7r)-7-{[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octan-2-yl]-1-oxa-4,7-diazacyclododec-7-ene-2,5-dione

C35H56N2O11 (680.3883906)


   

[(2r,3s,4s,5r,6r)-6-{[(1s,3ar,3br,5as,7r,8r,9s,9ar,9bs,11ar)-8,9-dihydroxy-1-[(2r)-2-hydroxy-6-methylhept-6-en-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

[(2r,3s,4s,5r,6r)-6-{[(1s,3ar,3br,5as,7r,8r,9s,9ar,9bs,11ar)-8,9-dihydroxy-1-[(2r)-2-hydroxy-6-methylhept-6-en-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

C38H64O10 (680.4499244)


   

8,16-dihydroxy-6-[3-hydroxy-2-(hydroxymethyl)prop-1-en-1-yl]-2,8,10,13,18,18-hexamethyl-17-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicos-19-en-12-one

8,16-dihydroxy-6-[3-hydroxy-2-(hydroxymethyl)prop-1-en-1-yl]-2,8,10,13,18,18-hexamethyl-17-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicos-19-en-12-one

C36H56O12 (680.3771576)


   

[(2r,3s,4s,5r,6r)-6-{[(1s,3ar,3br,5s,5ar,7s,9ar,9br,11r,11ar)-7,11-dihydroxy-1-[(2s)-2-hydroxy-6-methylhept-5-en-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-5-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

[(2r,3s,4s,5r,6r)-6-{[(1s,3ar,3br,5s,5ar,7s,9ar,9br,11r,11ar)-7,11-dihydroxy-1-[(2s)-2-hydroxy-6-methylhept-5-en-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-5-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

C38H64O10 (680.4499244)


   

[(2r,3s,4s,5r,6r)-6-{[(1s,3ar,3br,5as,7r,8r,9s,9ar,9bs,11ar)-8,9-dihydroxy-1-[(2r,4e)-2-hydroxy-6-methylhept-4-en-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

[(2r,3s,4s,5r,6r)-6-{[(1s,3ar,3br,5as,7r,8r,9s,9ar,9bs,11ar)-8,9-dihydroxy-1-[(2r,4e)-2-hydroxy-6-methylhept-4-en-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

C38H64O10 (680.4499244)


   

20,24-epoxycycloartane-3,12,15,16,25-pentol; (3β,12β,15α,16β,20ξ,24ξ)-form,15-ac,3-o-beta-d-xylopyranoside

NA

C37H60O11 (680.413541)


{"Ingredient_id": "HBIN003379","Ingredient_name": "20,24-epoxycycloartane-3,12,15,16,25-pentol; (3\u03b2,12\u03b2,15\u03b1,16\u03b2,20\u03be,24\u03be)-form,15-ac,3-o-beta-d-xylopyranoside","Alias": "NA","Ingredient_formula": "C37H60O11","Ingredient_Smile": "NA","Ingredient_weight": "680.87","OB_score": "NA","CAS_id": "98046-82-3","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8782","PubChem_id": "NA","DrugBank_id": "NA"}

   

beesioside d

NA

C37H60O11 (680.413541)


{"Ingredient_id": "HBIN017678","Ingredient_name": "beesioside d","Alias": "NA","Ingredient_formula": "C37H60O11","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2195","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

beesioside iii

NA

C37H60O11 (680.413541)


{"Ingredient_id": "HBIN017685","Ingredient_name": "beesioside iii","Alias": "NA","Ingredient_formula": "C37H60O11","Ingredient_Smile": "CC(=O)OC1C(C(C2(C1(C3CCC4C(C(CCC45C3(C5)CC2O)OC6C(C(C(CO6)O)O)O)(C)C)C)C)C7(CCC(O7)C(C)(C)O)C)O","Ingredient_weight": "680.9 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2202","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "21637572","DrugBank_id": "NA"}

   

(1r,2r,3as,3bs,7r,8s,9ar,9br,11ar)-1-[(2r,4e)-2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl]-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

(1r,2r,3as,3bs,7r,8s,9ar,9br,11ar)-1-[(2r,4e)-2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl]-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

C36H56O12 (680.3771576)


   

(2r,3r,4r,4ar,6ar,6bs,8ar,12s,12as,14ar,14br)-2,3,12-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

(2r,3r,4r,4ar,6ar,6bs,8ar,12s,12as,14ar,14br)-2,3,12-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


   

2-hydroxy-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl octadec-9-enoate

2-hydroxy-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl octadec-9-enoate

C33H60O14 (680.398286)


   

(2s)-2-[(3r,4s,8r,9r,10r,11s,14s)-8-{[(2s,3s,4r,5s,6s)-5-(acetyloxy)-3,4-dihydroxy-6-{[(2-methylbut-3-en-2-yl)oxy]methyl}oxan-2-yl]oxy}-4,9-dihydroxy-14-(methoxymethyl)-3,10-dimethyltricyclo[9.3.0.0³,⁷]tetradeca-1,6-dien-6-yl]propyl acetate

(2s)-2-[(3r,4s,8r,9r,10r,11s,14s)-8-{[(2s,3s,4r,5s,6s)-5-(acetyloxy)-3,4-dihydroxy-6-{[(2-methylbut-3-en-2-yl)oxy]methyl}oxan-2-yl]oxy}-4,9-dihydroxy-14-(methoxymethyl)-3,10-dimethyltricyclo[9.3.0.0³,⁷]tetradeca-1,6-dien-6-yl]propyl acetate

C36H56O12 (680.3771576)


   

(2s)-2-[(1e,3r,4s,8r,9r,10r,11s,14s)-8-{[(2s,3r,4r,5r,6r)-4-(acetyloxy)-3,5-dihydroxy-6-{[(2-methylbut-3-en-2-yl)oxy]methyl}oxan-2-yl]oxy}-4,9-dihydroxy-14-(methoxymethyl)-3,10-dimethyltricyclo[9.3.0.0³,⁷]tetradeca-1,6-dien-6-yl]propyl acetate

(2s)-2-[(1e,3r,4s,8r,9r,10r,11s,14s)-8-{[(2s,3r,4r,5r,6r)-4-(acetyloxy)-3,5-dihydroxy-6-{[(2-methylbut-3-en-2-yl)oxy]methyl}oxan-2-yl]oxy}-4,9-dihydroxy-14-(methoxymethyl)-3,10-dimethyltricyclo[9.3.0.0³,⁷]tetradeca-1,6-dien-6-yl]propyl acetate

C36H56O12 (680.3771576)


   

(3s,4r,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-3,12-dihydroxy-4-(hydroxymethyl)-6a,6b,11,12,14b-pentamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

(3s,4r,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-3,12-dihydroxy-4-(hydroxymethyl)-6a,6b,11,12,14b-pentamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


   

4,5-dihydroxy-2-({10-hydroxy-1-[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl}oxy)-6-(hydroxymethyl)oxan-3-yl acetate

4,5-dihydroxy-2-({10-hydroxy-1-[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl}oxy)-6-(hydroxymethyl)oxan-3-yl acetate

C38H64O10 (680.4499244)


   

(1r,3r,6s,8r,11r,12s,13r,14r,15r,16r,17r)-14,17-dihydroxy-15-[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-13-yl acetate

(1r,3r,6s,8r,11r,12s,13r,14r,15r,16r,17r)-14,17-dihydroxy-15-[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-13-yl acetate

C37H60O11 (680.413541)


   

4-[(1r,3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,4s,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

4-[(1r,3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,4s,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

C36H56O12 (680.3771576)


   

(1s,2s,4r,6s,8s,9r,10r,13s,14r,16s,17r,21s)-8,17,21-trihydroxy-6-[(1e)-3-hydroxy-2-methylprop-1-en-1-yl]-2,8,10,13,18,18-hexamethyl-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicos-19-en-12-one

(1s,2s,4r,6s,8s,9r,10r,13s,14r,16s,17r,21s)-8,17,21-trihydroxy-6-[(1e)-3-hydroxy-2-methylprop-1-en-1-yl]-2,8,10,13,18,18-hexamethyl-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicos-19-en-12-one

C36H56O12 (680.3771576)


   

(2r,6r)-6-[(1r,3as,3br,4r,7r,9ar,9bs,11s,11ar)-4-{[(2r,3r,4s,5r,6r)-6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl]oxy}-7,11-dihydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylheptyl acetate

(2r,6r)-6-[(1r,3as,3br,4r,7r,9ar,9bs,11s,11ar)-4-{[(2r,3r,4s,5r,6r)-6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl]oxy}-7,11-dihydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylheptyl acetate

C37H60O11 (680.413541)


   

2-{3-[(4e)-6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]cyclohexa-2,5-diene-1,4-dione

2-{3-[(4e)-6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]cyclohexa-2,5-diene-1,4-dione

C44H56O6 (680.4076676)


   

(1r,2s,4ar,6as,6br,8ar,9r,10r,11r,12ar,12br,14br)-2,10,11-trihydroxy-1,2,6a,6b,9,12a-hexamethyl-9-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

(1r,2s,4ar,6as,6br,8ar,9r,10r,11r,12ar,12br,14br)-2,10,11-trihydroxy-1,2,6a,6b,9,12a-hexamethyl-9-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C36H56O12 (680.3771576)


   

3,12-dihydroxy-4-(hydroxymethyl)-6a,6b,11,12,14b-pentamethyl-8a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

3,12-dihydroxy-4-(hydroxymethyl)-6a,6b,11,12,14b-pentamethyl-8a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


   

(2r,3as,3bs,8s,9ar,9br,11ar)-1-[(2r)-2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl]-2-hydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,8h,9h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

(2r,3as,3bs,8s,9ar,9br,11ar)-1-[(2r)-2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl]-2-hydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,8h,9h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

C36H56O12 (680.3771576)


   

4-{3a-hydroxy-7-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl}-5h-furan-2-one

4-{3a-hydroxy-7-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl}-5h-furan-2-one

C36H56O12 (680.3771576)


   

methyl 6,9,12,15,18,23,27,32-octamethyl-21-oxo-30-(prop-1-en-2-yl)-2,25-dioxaoctacyclo[24.5.3.0¹,²⁶.0³,²⁴.0⁵,²².0⁶,¹⁹.0⁹,¹⁸.0¹⁰,¹⁵]tetratriaconta-3,5(22),19,23,32-pentaene-12-carboxylate

methyl 6,9,12,15,18,23,27,32-octamethyl-21-oxo-30-(prop-1-en-2-yl)-2,25-dioxaoctacyclo[24.5.3.0¹,²⁶.0³,²⁴.0⁵,²².0⁶,¹⁹.0⁹,¹⁸.0¹⁰,¹⁵]tetratriaconta-3,5(22),19,23,32-pentaene-12-carboxylate

C45H60O5 (680.444051)


   

2,10,11-trihydroxy-1,2,6a,6b,9,12a-hexamethyl-9-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

2,10,11-trihydroxy-1,2,6a,6b,9,12a-hexamethyl-9-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C36H56O12 (680.3771576)


   

4-[(1r,3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,4r,5s,6s)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

4-[(1r,3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,4r,5s,6s)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

C36H56O12 (680.3771576)


   

6-benzyl-8,10-dihydroxy-4-methyl-3-(sec-butyl)-12-[(7r)-7-{[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octan-2-yl]-1-oxa-4,7-diazacyclododec-7-ene-2,5-dione

6-benzyl-8,10-dihydroxy-4-methyl-3-(sec-butyl)-12-[(7r)-7-{[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octan-2-yl]-1-oxa-4,7-diazacyclododec-7-ene-2,5-dione

C35H56N2O11 (680.3883906)


   

6-[(5-hydroxy-6-{[1-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-2h,3h,3ah,3bh,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-4-methoxy-2-methyloxan-3-yl)oxy]-4-methoxy-2-methyloxan-3-yl acetate

6-[(5-hydroxy-6-{[1-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-2h,3h,3ah,3bh,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-4-methoxy-2-methyloxan-3-yl)oxy]-4-methoxy-2-methyloxan-3-yl acetate

C37H60O11 (680.413541)


   

(1r,2r,3as,3br,7r,8s,9ar,9br,11ar)-1-[(2r,4e)-2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl]-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

(1r,2r,3as,3br,7r,8s,9ar,9br,11ar)-1-[(2r,4e)-2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl]-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

C36H56O12 (680.3771576)


   

6,9-dimethyl (6r,9r)-10-[2-(3-ethylpiperidin-1-yl)ethyl]-6-{3-[2-(3-ethylpiperidin-1-yl)ethyl]-1h-indol-2-yl}-7h,8h,9h-pyrido[1,2-a]indole-6,9-dicarboxylate

6,9-dimethyl (6r,9r)-10-[2-(3-ethylpiperidin-1-yl)ethyl]-6-{3-[2-(3-ethylpiperidin-1-yl)ethyl]-1h-indol-2-yl}-7h,8h,9h-pyrido[1,2-a]indole-6,9-dicarboxylate

C42H56N4O4 (680.4301336)


   

2-{3-[6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)cyclohexa-2,5-diene-1,4-dione

2-{3-[6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)cyclohexa-2,5-diene-1,4-dione

C44H56O6 (680.4076676)


   

5-hydroxy-1-{2-hydroxy-6-methyl-7-[(3,4,5-trihydroxy-6-methoxyoxan-2-yl)oxy]hept-5-en-2-yl}-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl acetate

5-hydroxy-1-{2-hydroxy-6-methyl-7-[(3,4,5-trihydroxy-6-methoxyoxan-2-yl)oxy]hept-5-en-2-yl}-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl acetate

C38H64O10 (680.4499244)


   

2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


   

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 2-[1,10,11-trihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicen-4a-yl]acetate

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 2-[1,10,11-trihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicen-4a-yl]acetate

C37H60O11 (680.413541)


   

(2r,3r,4s,5s,6r)-2-{[(1r,2r,3ar,5as,7s,9as,11as)-1-[(2r,3s,3ar,5s,6s,6as)-2,6-dihydroxy-6-isopropyl-5-methoxy-5-methyl-tetrahydrofuro[3,2-b]furan-3-yl]-2-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2r,3r,4s,5s,6r)-2-{[(1r,2r,3ar,5as,7s,9as,11as)-1-[(2r,3s,3ar,5s,6s,6as)-2,6-dihydroxy-6-isopropyl-5-methoxy-5-methyl-tetrahydrofuro[3,2-b]furan-3-yl]-2-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C36H56O12 (680.3771576)


   

(2r,3r,4s,5s,6r)-2-{[(1s,3ar,3br,5as,7s,9as,9br,10r,11ar)-10-hydroxy-1-[(2s,5r)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl acetate

(2r,3r,4s,5s,6r)-2-{[(1s,3ar,3br,5as,7s,9as,9br,10r,11ar)-10-hydroxy-1-[(2s,5r)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl acetate

C38H64O10 (680.4499244)


   

(1s,3ar,3br,5s,5ar,7s,9ar,9br,11as)-5-hydroxy-1-[(2s,5e)-2-hydroxy-6-methyl-7-{[(2r,3r,4s,5s,6s)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]oxy}hept-5-en-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl acetate

(1s,3ar,3br,5s,5ar,7s,9ar,9br,11as)-5-hydroxy-1-[(2s,5e)-2-hydroxy-6-methyl-7-{[(2r,3r,4s,5s,6s)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]oxy}hept-5-en-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl acetate

C38H64O10 (680.4499244)


   

(1r,3r,6s,8r,11s,12s,13r,14r,15r,16r,17r)-14,17-dihydroxy-15-[(2s,5s)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-13-yl acetate

(1r,3r,6s,8r,11s,12s,13r,14r,15r,16r,17r)-14,17-dihydroxy-15-[(2s,5s)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-13-yl acetate

C37H60O11 (680.413541)


   

(2s,3r,4r,6s)-6-{[(2r,3s,4r,5r,6r)-6-{[(1r,3as,3br,5ar,7s,9as,9bs,11as)-1-hydroxy-1-[(1s)-1-hydroxyethyl]-9a,11a-dimethyl-2h,3h,3ah,3bh,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl]oxy}-4-methoxy-2-methyloxan-3-yl acetate

(2s,3r,4r,6s)-6-{[(2r,3s,4r,5r,6r)-6-{[(1r,3as,3br,5ar,7s,9as,9bs,11as)-1-hydroxy-1-[(1s)-1-hydroxyethyl]-9a,11a-dimethyl-2h,3h,3ah,3bh,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl]oxy}-4-methoxy-2-methyloxan-3-yl acetate

C37H60O11 (680.413541)


   

(2s,3r,4s,4ar,6ar,6br,8as,12ar,14ar,14br)-2-hydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid

(2s,3r,4s,4ar,6ar,6br,8as,12ar,14ar,14br)-2-hydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid

C36H56O12 (680.3771576)


   

(6s,6ar,10as,14r)-12-hexanoyl-7,10a,13-trihydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-6,6a,7,14-tetrahydro-5,11-dioxapentaphene-1,3,9-trione

(6s,6ar,10as,14r)-12-hexanoyl-7,10a,13-trihydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-6,6a,7,14-tetrahydro-5,11-dioxapentaphene-1,3,9-trione

C40H56O9 (680.3924126000001)


   

4-[(1s,3as,3br,5as,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,4r,5s,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

4-[(1s,3as,3br,5as,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,4r,5s,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

C36H56O12 (680.3771576)


   

(2s,4s,6ar,8as,14br)-2-hydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid

(2s,4s,6ar,8as,14br)-2-hydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid

C36H56O12 (680.3771576)


   

{3,4,5-trihydroxy-6-[(6-methyl-2-{5,7,11-trihydroxy-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl}hept-5-en-2-yl)oxy]oxan-2-yl}methyl acetate

{3,4,5-trihydroxy-6-[(6-methyl-2-{5,7,11-trihydroxy-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl}hept-5-en-2-yl)oxy]oxan-2-yl}methyl acetate

C38H64O10 (680.4499244)


   

methyl (4ar,5r,6as,6br,8ar,9r,10r,11s,12ar,12br,14bs)-5,11-dihydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

methyl (4ar,5r,6as,6br,8ar,9r,10r,11s,12ar,12br,14bs)-5,11-dihydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C37H60O11 (680.413541)


   

[(2r,3s,4s,5r,6s)-6-{[(2s)-2-[(1s,3ar,3br,5s,5ar,7s,9ar,9br,11r,11ar)-5,7,11-trihydroxy-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-en-2-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

[(2r,3s,4s,5r,6s)-6-{[(2s)-2-[(1s,3ar,3br,5s,5ar,7s,9ar,9br,11r,11ar)-5,7,11-trihydroxy-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-en-2-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

C38H64O10 (680.4499244)


   

(2r,3r,4s,5s,6r)-2-{[(1s,3ar,3br,5as,7r,8r,9s,9ar,9bs,11ar)-8,9-dihydroxy-1-[(2r)-2-hydroxy-6-methylhept-6-en-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl acetate

(2r,3r,4s,5s,6r)-2-{[(1s,3ar,3br,5as,7r,8r,9s,9ar,9bs,11ar)-8,9-dihydroxy-1-[(2r)-2-hydroxy-6-methylhept-6-en-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl acetate

C38H64O10 (680.4499244)


   

4-{3-[(4e)-6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]cyclohexa-3,5-diene-1,2-dione

4-{3-[(4e)-6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]cyclohexa-3,5-diene-1,2-dione

C44H56O6 (680.4076676)


   

(2s,3r,4s,4ar,6ar,6br,8as,12as,14ar,14br)-2-hydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid

(2s,3r,4s,4ar,6ar,6br,8as,12as,14ar,14br)-2-hydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid

C36H56O12 (680.3771576)


   

methyl 5,11-dihydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

methyl 5,11-dihydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C37H60O11 (680.413541)


   

(2s)-2-[(1e,3r,4s,8r,9r,10r,11s,14s)-8-{[(2s,3s,4r,5s,6s)-5-(acetyloxy)-3,4-dihydroxy-6-{[(2-methylbut-3-en-2-yl)oxy]methyl}oxan-2-yl]oxy}-4,9-dihydroxy-14-(methoxymethyl)-3,10-dimethyltricyclo[9.3.0.0³,⁷]tetradeca-1,6-dien-6-yl]propyl acetate

(2s)-2-[(1e,3r,4s,8r,9r,10r,11s,14s)-8-{[(2s,3s,4r,5s,6s)-5-(acetyloxy)-3,4-dihydroxy-6-{[(2-methylbut-3-en-2-yl)oxy]methyl}oxan-2-yl]oxy}-4,9-dihydroxy-14-(methoxymethyl)-3,10-dimethyltricyclo[9.3.0.0³,⁷]tetradeca-1,6-dien-6-yl]propyl acetate

C36H56O12 (680.3771576)


   

(1s,2s,4r,6s,8s,9r,10r,13r,14r,16s,17s)-8,16-dihydroxy-6-[3-hydroxy-2-(hydroxymethyl)prop-1-en-1-yl]-2,8,10,13,18,18-hexamethyl-17-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicos-19-en-12-one

(1s,2s,4r,6s,8s,9r,10r,13r,14r,16s,17s)-8,16-dihydroxy-6-[3-hydroxy-2-(hydroxymethyl)prop-1-en-1-yl]-2,8,10,13,18,18-hexamethyl-17-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicos-19-en-12-one

C36H56O12 (680.3771576)


   

4-[(1r,3as,3br,5as,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,4s,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

4-[(1r,3as,3br,5as,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,4s,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

C36H56O12 (680.3771576)


   

8,17,21-trihydroxy-6-(3-hydroxy-2-methylprop-1-en-1-yl)-2,8,10,13,18,18-hexamethyl-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicos-19-en-12-one

8,17,21-trihydroxy-6-(3-hydroxy-2-methylprop-1-en-1-yl)-2,8,10,13,18,18-hexamethyl-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicos-19-en-12-one

C36H56O12 (680.3771576)


   

2,3,12-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

2,3,12-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


   

(1r,2s,4ar,6as,6br,8ar,9r,10r,11r,12ar,12br,14bs)-2,10,11-trihydroxy-1,2,6a,6b,9,12a-hexamethyl-9-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

(1r,2s,4ar,6as,6br,8ar,9r,10r,11r,12ar,12br,14bs)-2,10,11-trihydroxy-1,2,6a,6b,9,12a-hexamethyl-9-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C36H56O12 (680.3771576)


   

2-[(1-{2,6-dihydroxy-6-isopropyl-5-methoxy-5-methyl-tetrahydrofuro[3,2-b]furan-3-yl}-2-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

2-[(1-{2,6-dihydroxy-6-isopropyl-5-methoxy-5-methyl-tetrahydrofuro[3,2-b]furan-3-yl}-2-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C36H56O12 (680.3771576)


   

(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 2-[(1r,2r,4ar,6as,6br,8as,9r,10r,11r,12ar,12br,14br)-1,10,11-trihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicen-4a-yl]acetate

(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 2-[(1r,2r,4ar,6as,6br,8as,9r,10r,11r,12ar,12br,14br)-1,10,11-trihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicen-4a-yl]acetate

C37H60O11 (680.413541)


   

(1s,4r,5r,6r,10s,12s,13s,15s,16r,18s,21r)-18-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-15-hydroxy-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-one

(1s,4r,5r,6r,10s,12s,13s,15s,16r,18s,21r)-18-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-15-hydroxy-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-one

C36H56O12 (680.3771576)


   

2-[(3r,4s,10r,11s,14s)-8-{[(2s,4s,6r)-4-(acetyloxy)-3,5-dihydroxy-6-{[(2-methylbut-3-en-2-yl)oxy]methyl}oxan-2-yl]oxy}-4,9-dihydroxy-14-(methoxymethyl)-3,10-dimethyltricyclo[9.3.0.0³,⁷]tetradeca-1,6-dien-6-yl]propyl acetate

2-[(3r,4s,10r,11s,14s)-8-{[(2s,4s,6r)-4-(acetyloxy)-3,5-dihydroxy-6-{[(2-methylbut-3-en-2-yl)oxy]methyl}oxan-2-yl]oxy}-4,9-dihydroxy-14-(methoxymethyl)-3,10-dimethyltricyclo[9.3.0.0³,⁷]tetradeca-1,6-dien-6-yl]propyl acetate

C36H56O12 (680.3771576)


   

18-({4,5-dihydroxy-3-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-15-hydroxy-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-one

18-({4,5-dihydroxy-3-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-15-hydroxy-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-one

C36H56O12 (680.3771576)


   

(4s,4ar,6ar,6br,8as,12as,14ar,14br)-2-hydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid

(4s,4ar,6ar,6br,8as,12as,14ar,14br)-2-hydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid

C36H56O12 (680.3771576)


   

(2r,3r,4s,4ar,6ar,6bs,8ar,12s,12as,14ar,14br)-2,3,12-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

(2r,3r,4s,4ar,6ar,6bs,8ar,12s,12as,14ar,14br)-2,3,12-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


   

4-{3-[6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)cyclohexa-3,5-diene-1,2-dione

4-{3-[6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)cyclohexa-3,5-diene-1,2-dione

C44H56O6 (680.4076676)


   

(1s)-1-[(1s,4r,5r,6r,8r,10r,11r,12s,13r,16r,18s,21r)-10,11-dihydroxy-4,6,12,17,17-pentamethyl-18-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl]-2-hydroxy-2-methylpropyl acetate

(1s)-1-[(1s,4r,5r,6r,8r,10r,11r,12s,13r,16r,18s,21r)-10,11-dihydroxy-4,6,12,17,17-pentamethyl-18-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl]-2-hydroxy-2-methylpropyl acetate

C37H60O11 (680.413541)


   

(2s)-2-hydroxy-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl (9z)-octadec-9-enoate

(2s)-2-hydroxy-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl (9z)-octadec-9-enoate

C33H60O14 (680.398286)


   

1-(2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl)-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

1-(2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl)-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

C36H56O12 (680.3771576)


   

(2r,3r,4s,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

(2r,3r,4s,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


   

14,17-dihydroxy-15-[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(3,4,5-trihydroxyoxan-2-yl)oxy]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-13-yl acetate

14,17-dihydroxy-15-[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(3,4,5-trihydroxyoxan-2-yl)oxy]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-13-yl acetate

C37H60O11 (680.413541)


   

(2r,3r,4r,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

(2r,3r,4r,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


   

methyl (1s,6r,9s,12r,15s,18s,26s)-6,9,12,15,18,23,27,32-octamethyl-21-oxo-30-(prop-1-en-2-yl)-2,25-dioxaoctacyclo[24.5.3.0¹,²⁶.0³,²⁴.0⁵,²².0⁶,¹⁹.0⁹,¹⁸.0¹⁰,¹⁵]tetratriaconta-3,5(22),19,23,32-pentaene-12-carboxylate

methyl (1s,6r,9s,12r,15s,18s,26s)-6,9,12,15,18,23,27,32-octamethyl-21-oxo-30-(prop-1-en-2-yl)-2,25-dioxaoctacyclo[24.5.3.0¹,²⁶.0³,²⁴.0⁵,²².0⁶,¹⁹.0⁹,¹⁸.0¹⁰,¹⁵]tetratriaconta-3,5(22),19,23,32-pentaene-12-carboxylate

C45H60O5 (680.444051)


   

(2r,3r,4s,4as,6ar,6bs,8as,11r,12r,12ar,14ar,14br)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

(2r,3r,4s,4as,6ar,6bs,8as,11r,12r,12ar,14ar,14br)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O12 (680.3771576)


   

methyl (1s,6r,9s,10r,12r,15s,18s,26s,27r,30r)-6,9,12,15,18,23,27,32-octamethyl-21-oxo-30-(prop-1-en-2-yl)-2,25-dioxaoctacyclo[24.5.3.0¹,²⁶.0³,²⁴.0⁵,²².0⁶,¹⁹.0⁹,¹⁸.0¹⁰,¹⁵]tetratriaconta-3,5(22),19,23,32-pentaene-12-carboxylate

methyl (1s,6r,9s,10r,12r,15s,18s,26s,27r,30r)-6,9,12,15,18,23,27,32-octamethyl-21-oxo-30-(prop-1-en-2-yl)-2,25-dioxaoctacyclo[24.5.3.0¹,²⁶.0³,²⁴.0⁵,²².0⁶,¹⁹.0⁹,¹⁸.0¹⁰,¹⁵]tetratriaconta-3,5(22),19,23,32-pentaene-12-carboxylate

C45H60O5 (680.444051)


   
   

1-{10,11-dihydroxy-4,6,12,17,17-pentamethyl-18-[(3,4,5-trihydroxyoxan-2-yl)oxy]-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl}-2-hydroxy-2-methylpropyl acetate

1-{10,11-dihydroxy-4,6,12,17,17-pentamethyl-18-[(3,4,5-trihydroxyoxan-2-yl)oxy]-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl}-2-hydroxy-2-methylpropyl acetate

C37H60O11 (680.413541)


   

4-[(1s,3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,4r,5s,6s)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

4-[(1s,3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,4r,5s,6s)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

C36H56O12 (680.3771576)